These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 37196887)
1. Health Characteristics and Aspirin Use in Participants at the Baseline of the ASPirin in Reducing Events in the Elderly - eXTension (ASPREE-XT) Observational Study. Ernst ME; Broder JC; Wolfe R; Woods RL; Nelson MR; Ryan J; Shah RC; Orchard SG; Chan AT; Espinoza SE; Wilson M; Kirpach B; Reid CM; McNeil JJ; Williamson JD; Murray AM; Contemp Clin Trials; 2023 Jul; 130():107231. PubMed ID: 37196887 [TBL] [Abstract][Full Text] [Related]
2. Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. McNeil JJ; Woods RL; Nelson MR; Murray AM; Reid CM; Kirpach B; Storey E; Shah RC; Wolfe RS; Tonkin AM; Newman AB; Williamson JD; Lockery JE; Margolis KL; Ernst ME; Abhayaratna WP; Stocks N; Fitzgerald SM; Trevaks RE; Orchard SG; Beilin LJ; Donnan GA; Gibbs P; Johnston CI; Grimm RH; J Gerontol A Biol Sci Med Sci; 2017 Oct; 72(11):1586-1593. PubMed ID: 28329340 [TBL] [Abstract][Full Text] [Related]
3. Expanded statistical analysis plan for legacy and long-term effects of aspirin in the ASPREE-XT observational follow-up study of participants in the ASPREE randomized trial. Wolfe R; Broder J; Chan A; Murray A; Orchard S; Polekhina G; Ryan J; Tonkin A; Webb K; Woods R medRxiv; 2023 Sep; ():. PubMed ID: 37745426 [TBL] [Abstract][Full Text] [Related]
4. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. ASPREE Investigator Group Contemp Clin Trials; 2013 Nov; 36(2):555-64. PubMed ID: 24113028 [TBL] [Abstract][Full Text] [Related]
5. ASPREE-NEURO study protocol: A randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly. Ward SA; Raniga P; Ferris NJ; Woods RL; Storey E; Bailey MJ; Brodtmann A; Yates PA; Donnan GA; Trevaks RE; Wolfe R; Egan GF; McNeil JJ; Int J Stroke; 2017 Jan; 12(1):108-113. PubMed ID: 27634976 [TBL] [Abstract][Full Text] [Related]
6. Prescription Medication Use in Older Adults Without Major Cardiovascular Disease Enrolled in the Aspirin in Reducing Events in the Elderly (ASPREE) Clinical Trial. Lockery JE; Ernst ME; Broder JC; Orchard SG; Murray A; Nelson MR; Stocks NP; Wolfe R; Reid CM; Liew D; Woods RL; Pharmacotherapy; 2020 Oct; 40(10):1042-1053. PubMed ID: 33078479 [TBL] [Abstract][Full Text] [Related]
7. Low-Dose Aspirin and Progression of Age-Related Hearing Loss: A Secondary Analysis of the ASPREE Randomized Clinical Trial. Clark DPQ; Zhou Z; Hussain SM; Tran C; Britt C; Storey E; Lowthian JA; Shah RC; Dillon H; Wolfe R; Woods RL; Rance G; McNeil JJ JAMA Netw Open; 2024 Jul; 7(7):e2424373. PubMed ID: 39052288 [TBL] [Abstract][Full Text] [Related]
8. A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: protocol for the ASPREE-Fracture substudy. Barker AL; McNeil JJ; Seeman E; Ward SA; Sanders KM; Khosla S; Cumming RG; Pasco JA; Bohensky MA; Ebeling PR; Woods RL; Lockery JE; Wolfe R; Talevski J; Inj Prev; 2016 Aug; 22(4):297-301. PubMed ID: 26002770 [TBL] [Abstract][Full Text] [Related]
9. Slowing the progression of age-related hearing loss: Rationale and study design of the ASPIRIN in HEARING, retinal vessels imaging and neurocognition in older generations (ASPREE-HEARING) trial. Lowthian JA; Britt CJ; Rance G; Lin FR; Woods RL; Wolfe R; Nelson MR; Dillon HA; Ward S; Reid CM; Lockery JE; Nguyen TT; McNeil JJ; Storey E; Contemp Clin Trials; 2016 Jan; 46():60-66. PubMed ID: 26611434 [TBL] [Abstract][Full Text] [Related]
10. Effect of Low-Dose Aspirin on the Course of Age-Related Macular Degeneration: A Secondary Analysis of the ASPREE Randomized Clinical Trial. Robman LD; Wolfe R; Woods RL; Thao LTP; Makeyeva GA; Hodgson LAB; Lepham YA; Jachno K; Phung J; Maguire E; Luong H; Trevaks RE; Ward SA; Fitzgerald SM; Orchard SG; Lacaze P; Storey E; Abhayaratna WP; Nelson MR; Guymer RH; McNeil JJ JAMA Ophthalmol; 2024 Jul; 142(7):627-635. PubMed ID: 38780931 [TBL] [Abstract][Full Text] [Related]
11. Daily Low-Dose Aspirin and Risk of Serious Falls and Fractures in Healthy Older People: A Substudy of the ASPREE Randomized Clinical Trial. Barker AL; Morello R; Thao LTP; Seeman E; Ward SA; Sanders KM; Cumming RG; Pasco JA; Ebeling PR; Woods RL; Wolfe R; Khosla S; Hussain SM; Ronaldson K; Newman AB; Williamson JD; McNeil JJ JAMA Intern Med; 2022 Dec; 182(12):1289-1297. PubMed ID: 36342703 [TBL] [Abstract][Full Text] [Related]
12. Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial. Orchard SG; Lockery JE; Gibbs P; Polekhina G; Wolfe R; Zalcberg J; Haydon A; McNeil JJ; Nelson MR; Reid CM; Kirpach B; Murray AM; Woods RL; Contemp Clin Trials; 2020 Sep; 96():106095. PubMed ID: 32739494 [TBL] [Abstract][Full Text] [Related]
13. Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial. Zoungas S; Zhou Z; Owen AJ; Curtis AJ; Espinoza SE; Ernst ME; Woods RL; Orchard SG; McNeil JJ; Murray AM; Nelson MR; Reid CM; Ryan J; Wolfe R Lancet Diabetes Endocrinol; 2024 Feb; 12(2):98-106. PubMed ID: 38142708 [TBL] [Abstract][Full Text] [Related]
14. A Thorough Literature Review of the Potential Benefits and Drawbacks of Long-Term Aspirin Use for the Primary Prevention of Cardiovascular Disease. Shubietah ARM; Marin MP; Rajab IM; Oweidat MH; Zayed A; Hmeedan A Cardiol Rev; 2024 May; ():. PubMed ID: 38785443 [TBL] [Abstract][Full Text] [Related]
15. The Study of Neurocognitive Outcomes, Radiological and Retinal Effects of Aspirin in Sleep Apnoea- rationale and methodology of the SNORE-ASA study. Ward SA; Storey E; Woods RL; Hamilton GS; Kawasaki R; Janke AL; Naughton MT; O'Donoghue F; Wolfe R; Wong TY; Reid CM; Abhayaratna WP; Stocks N; Trevaks R; Fitzgerald S; Hodgson LAB; Robman L; Workman B; McNeil JJ; Contemp Clin Trials; 2018 Jan; 64():101-111. PubMed ID: 29097299 [TBL] [Abstract][Full Text] [Related]
16. Similar mortality risk in incident cognitive impairment and dementia: Evidence from the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Lin X; Banaszak-Holl J; Xie J; Ward SA; Brodaty H; Storey E; Shah RC; Murray A; Ryan J; Orchard SG; Fitzgerald SM; McNeil JJ J Am Geriatr Soc; 2021 Dec; 69(12):3568-3575. PubMed ID: 34533211 [TBL] [Abstract][Full Text] [Related]
17. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Nelson MR; Reid CM; Ames DA; Beilin LJ; Donnan GA; Gibbs P; Johnston CI; Krum H; Storey E; Tonkin A; Wolfe R; Woods R; McNeil JJ Med J Aust; 2008 Jul; 189(2):105-9. PubMed ID: 18637782 [TBL] [Abstract][Full Text] [Related]
18. Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Wolfe R; Wetmore JB; Woods RL; McNeil JJ; Gallagher H; Roderick P; Walker R; Nelson MR; Reid CM; Shah RC; Ernst ME; Lockery JE; Tonkin AM; Abhayaratna WP; Gibbs P; Wood EM; Mahady SE; Williamson JD; Donnan GA; Cloud GC; Murray AM; Polkinghorne KR Kidney Int; 2021 Feb; 99(2):466-474. PubMed ID: 32920022 [TBL] [Abstract][Full Text] [Related]